More from Raging Bull:
I hear that the video clip on this previously posted link will be sent to some news organizations.
newstream.com
Click on the "Preview" button on the upper right side of the screen.
When people come to realize that they can still get this stock at pre-clinical trial levels and the the only reason for the price decline was the poor financing deal Neotherapeutics got into, this stock will take off.
Anybody who believes that Neotherapeutics will stay below the radar screen and that there will be plenty of time to get in before the full potential is realized will miss one of the buys of a lifetime. Too many people know about it already... including some big savvy investors.
So sorry for Strong River and Montrose who no doubt shorted it down to 4 and 5, thinking they would get shares at those levels from the Company to cover. They probably thought they could force it lower by the last reset date but it turns out there are always forces bigger and stronger than they ever imagined. I hope this news and this move busts them out.
................
The big savvy investor referred to above is Peter Kellogg, chief of Spear, Leeds & Kellogg, the largest specialist firm on the NYSE and AMEX, purchased last fall by Goldman Sachs last fall for $6.3 billion. He bought 880,000 shares of NEOT.
So, with the conclusions of the DD you can presume he no doubt did, plus the capital and retail marketing resources available to Goldman Sachs, plus the recent news release and video on NEOT, plus the large scale pivotal clinical trials on starting in April, plus, plus, plus, you could say it is a good time to be in NEOT. |
